These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Emptying the stores: lysosomal diseases and therapeutic strategies. Platt FM Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032 [TBL] [Abstract][Full Text] [Related]
25. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Fan JQ Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864 [TBL] [Abstract][Full Text] [Related]
26. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases. Oh DB BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178 [TBL] [Abstract][Full Text] [Related]
27. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. Parenti G EMBO Mol Med; 2009 Aug; 1(5):268-79. PubMed ID: 20049730 [TBL] [Abstract][Full Text] [Related]
28. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520 [TBL] [Abstract][Full Text] [Related]
29. [Therapy of lysosomal storage diseases: update and perspectives]. Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678 [TBL] [Abstract][Full Text] [Related]
30. Current state of the management of LSDs. Germain DP; Aggio M Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S61-2. PubMed ID: 20040313 [No Abstract] [Full Text] [Related]
33. Reversibility of cellular and organ pathology in enzyme replacement trials in animal models of lysosomal storage diseases. Gieselmann V Acta Paediatr Suppl; 2006 Apr; 95(451):93-9. PubMed ID: 16720473 [TBL] [Abstract][Full Text] [Related]
34. Treating lysosomal storage disorders: What have we learnt? Lachmann RH J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601 [TBL] [Abstract][Full Text] [Related]
35. [Musculoskeletal manifestations in lysosomal storage diseases]. Kovac I Reumatizam; 2011; 58(2):182-4. PubMed ID: 22232961 [TBL] [Abstract][Full Text] [Related]
36. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Dickson PI Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323 [TBL] [Abstract][Full Text] [Related]
37. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628 [TBL] [Abstract][Full Text] [Related]
38. Treatment options for lysosomal storage disorders: developing insights. van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070 [TBL] [Abstract][Full Text] [Related]